213 related articles for article (PubMed ID: 15034041)
1. Smad3 is essential for TGF-beta 1 to suppress IL-2 production and TCR-induced proliferation, but not IL-2-induced proliferation.
McKarns SC; Schwartz RH; Kaminski NE
J Immunol; 2004 Apr; 172(7):4275-84. PubMed ID: 15034041
[TBL] [Abstract][Full Text] [Related]
2. Beta-hydroxybutyrate-induced growth inhibition and collagen production in HK-2 cells are dependent on TGF-beta and Smad3.
Guh JY; Chuang TD; Chen HC; Hung WC; Lai YH; Shin SJ; Chuang LY
Kidney Int; 2003 Dec; 64(6):2041-51. PubMed ID: 14633126
[TBL] [Abstract][Full Text] [Related]
3. The role of Smad3 in mediating mouse hepatic stellate cell activation.
Schnabl B; Kweon YO; Frederick JP; Wang XF; Rippe RA; Brenner DA
Hepatology; 2001 Jul; 34(1):89-100. PubMed ID: 11431738
[TBL] [Abstract][Full Text] [Related]
4. The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells.
Poncelet AC; de Caestecker MP; Schnaper HW
Kidney Int; 1999 Oct; 56(4):1354-65. PubMed ID: 10504488
[TBL] [Abstract][Full Text] [Related]
5. Uncoupling of promitogenic and antiapoptotic functions of IL-2 by Smad-dependent TGF-beta signaling.
Nelson BH; Martyak TP; Thompson LJ; Moon JJ; Wang T
J Immunol; 2003 Jun; 170(11):5563-70. PubMed ID: 12759434
[TBL] [Abstract][Full Text] [Related]
6. Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3-deficient fibroblasts.
Piek E; Ju WJ; Heyer J; Escalante-Alcalde D; Stewart CL; Weinstein M; Deng C; Kucherlapati R; Bottinger EP; Roberts AB
J Biol Chem; 2001 Jun; 276(23):19945-53. PubMed ID: 11262418
[TBL] [Abstract][Full Text] [Related]
7. CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness.
Piccirillo CA; Letterio JJ; Thornton AM; McHugh RS; Mamura M; Mizuhara H; Shevach EM
J Exp Med; 2002 Jul; 196(2):237-46. PubMed ID: 12119348
[TBL] [Abstract][Full Text] [Related]
8. Resistance to TGF-beta1-mediated growth inhibition correlates with sustained Smad2 phosphorylation in primary murine splenocytes.
Feldmann K; Sebald W; Knaus P
Eur J Immunol; 2002 May; 32(5):1393-402. PubMed ID: 11981827
[TBL] [Abstract][Full Text] [Related]
9. Reduced Smad3 protein expression and altered transforming growth factor-beta1-mediated signaling in cystic fibrosis epithelial cells.
Kelley TJ; Elmer HL; Corey DA
Am J Respir Cell Mol Biol; 2001 Dec; 25(6):732-8. PubMed ID: 11726399
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways.
Park JI; Lee MG; Cho K; Park BJ; Chae KS; Byun DS; Ryu BK; Park YK; Chi SG
Oncogene; 2003 Jul; 22(28):4314-32. PubMed ID: 12853969
[TBL] [Abstract][Full Text] [Related]
11. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease.
Monteleone G; Kumberova A; Croft NM; McKenzie C; Steer HW; MacDonald TT
J Clin Invest; 2001 Aug; 108(4):601-9. PubMed ID: 11518734
[TBL] [Abstract][Full Text] [Related]
12. Smad2 and 3 mediate transforming growth factor-beta1-induced inhibition of chondrocyte maturation.
Ferguson CM; Schwarz EM; Reynolds PR; Puzas JE; Rosier RN; O'Keefe RJ
Endocrinology; 2000 Dec; 141(12):4728-35. PubMed ID: 11108288
[TBL] [Abstract][Full Text] [Related]
13. Human T-cell lymphotropic virus oncoprotein Tax represses TGF-beta 1 signaling in human T cells via c-Jun activation: a potential mechanism of HTLV-I leukemogenesis.
Arnulf B; Villemain A; Nicot C; Mordelet E; Charneau P; Kersual J; Zermati Y; Mauviel A; Bazarbachi A; Hermine O
Blood; 2002 Dec; 100(12):4129-38. PubMed ID: 12393612
[TBL] [Abstract][Full Text] [Related]
14. CD28 co-stimulation regulates the effect of transforming growth factor-beta1 on the proliferation of naïve CD4+ T cells.
Sung JL; Lin JT; Gorham JD
Int Immunopharmacol; 2003 Feb; 3(2):233-45. PubMed ID: 12586604
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-beta (TGF-beta ) and the type II TGF-beta receptor.
Fanayan S; Firth SM; Butt AJ; Baxter RC
J Biol Chem; 2000 Dec; 275(50):39146-51. PubMed ID: 10993898
[TBL] [Abstract][Full Text] [Related]
16. Smad7 is a TGF-beta-inducible attenuator of Smad2/3-mediated inhibition of embryonic lung morphogenesis.
Zhao J; Crowe DL; Castillo C; Wuenschell C; Chai Y; Warburton D
Mech Dev; 2000 May; 93(1-2):71-81. PubMed ID: 10781941
[TBL] [Abstract][Full Text] [Related]
17. Smad3: a key player in pathogenetic mechanisms dependent on TGF-beta.
Roberts AB; Russo A; Felici A; Flanders KC
Ann N Y Acad Sci; 2003 May; 995():1-10. PubMed ID: 12814934
[TBL] [Abstract][Full Text] [Related]
18. SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system.
Schiemann BJ; Neil JR; Schiemann WP
Mol Biol Cell; 2003 Oct; 14(10):3977-88. PubMed ID: 14517312
[TBL] [Abstract][Full Text] [Related]
19. Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells.
Hayashida T; Decaestecker M; Schnaper HW
FASEB J; 2003 Aug; 17(11):1576-8. PubMed ID: 12824291
[TBL] [Abstract][Full Text] [Related]
20. Alteration of transforming growth factor-beta1 response involves down-regulation of Smad3 signaling in myofibroblasts from skin fibrosis.
Reisdorf P; Lawrence DA; Sivan V; Klising E; Martin MT
Am J Pathol; 2001 Jul; 159(1):263-72. PubMed ID: 11438473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
